Big picture - Why invest in MaxCyte
Driving a New Generation of Cell-based Medicines
We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.
This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.
We are developing CARMA, our proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture chimeric antigen receptor (CAR) therapies for a broad range of cancer indications, including solid tumors where existing chimeric antigen receptor T cell (CAR-T) approaches face significant challenges.
We understand and scientifically solve partners’ challenges by applying our expertise and proven delivery platform for cell-engineering.
At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use more cost-effectively and with lowered risk.
Our broad intellectual property (IP) portfolio, along with our regulatory certifications and support, offer our partners both enhanced IP protection and broad freedom to operate.
Scientists are just beginning to unravel the complexities of cells, their regulation, and their relationship to disease. As our understanding continues to grow, it reveals new avenues for therapeutic interventions and curative efforts.
Cell-engineering looks to unlock the power of cells for a variety of applications including the discovery, development and manufacture of novel small molecule drugs and biologics, the biomanufacturing of vaccines and biotherapeutics, the re-direction or enhancement of cells for use as cellular therapies and the modification of targeted genes in cells for therapeutic purposes through genomic editing.
We have developed and commercialized MaxCyte Scalable Transfection Systems for high-performance delivery of biomolecules using Flow Electroporation™ Technology, a proprietary cell-engineering technology designed to meet the stringent demands of clinical use – namely the ability to safely and reproducibly modify primary human cells with high efficiency, low cytotoxicity, and at the scale required to treat patients. Flow
Electroporation Technology leverages a fundamental property of cells – the reversible permeability of membranes in the presence of an electrical charge – to create a transformative method for universally delivering molecules such as nucleic acids and proteins into cells, turning cells into drugs, etc.
Unlike other methods, Flow Electroporation Technology is a fully scalable, delivery platform that enables small-scale R&D through large-scale cell-engineering for global patient treatment. It is the leading non-viral delivery platform for cell-engineering in clinical use with an approved commercial immunotherapy in Japan and is currently being used in 10+ clinical trials.
We pair our high-performance delivery platform with our cell-engineering expertise to accelerate the discovery, development and manufacturing of next-generation, cell-based medicines – overcoming client challenges and enabling previously unfeasible cell-engineering applications.
As a company, we are dedicated to advancing cell-engineering through application of its patented delivery platform and collaborative partnerships. We are uniquely positioned at the center of cell therapy and gene editing: able to unlock the full power of the human cell to maximize the potential of these promising modalities.
MaxCyte has developed a novel and proprietary platform for next-generation chimeric antigen receptor (CAR)-engineered T/NK-cell therapies. Our CAR platform provides several unique attributes versus existing autologous CAR-T products and platforms. To read more click here.
Products and Services
MaxCyte is the trusted provider of high-performance, cell-engineering solutions and expertise.
Harness the power of the cell using one of our Scalable Transfection Systems or our custom Insourcing services.
Our Scalable Transfection Systems provide superior cell-engineering and seamlessly scale for efficient migration from early research to commercial manufacturing. Each system is tailored to meet the scalability and regulatory support needs for specific cell-engineering uses.
The MaxCyte STX® engineers from half a million (0.5 x 106) to 20 billion cells (2 x 1010) to support R&D from early-stage development through pre-clinical work.
The MaxCyte VLX® engineers from half a million (0.5 x 106 ) to 200 billion cells (2 x 1011) to support R&D through biomanufacturing.
The MaxCyte GT® has the scalability and established regulatory record for the development and manufacturing of clinical, cell and gene therapies.
ALL OUR SCALABLE TRANSFECTION SYSTEMS ARE:
Based on Flow Electroporation™ Technology with seamless scalability
Closed, computer-controlled instruments that are cGMP-compliant, ISO-certified and CE-marked
Supported by FDA master file, offering a clear regulatory pathway
To read more click here.
Any Cell. Any Molecule. Any Scale.®
Our delivery platform for cell engineering uses a non-viral, reproducible technology with high-level performance, flexibility and unmatched scalability.
MaxCyte’s cell engineering platform is based on Flow Electroporation™ Technology, a universal transfection technology capable of high-performance delivery of virtually any molecule, to any cell, at any scale. It has the unique ability to transfect primary cells, stem cells and cell lines with minimal cell disturbance and transfection efficiencies routinely >90% for a variety of cell types – rates that exceed those of other transfection methods. Flow Electroporation Technology is an inherently safe technology with a clear regulatory pathway that provides scientists with the freedom to use the most physiologically relevant system facilitating the identification, development and manufacturing of cell therapies, biotherapeutics and small molecule candidates of the highest quality. To read more please click here.
President and Chief Executive Officer
Mr. Doerfler has more than 35 years of experience in the discovery, development, commercialisation and international financing of biotechnology products and companies. He was a founder of MaxCyte in July 1998. Previously, Mr. Doerfler was President, Chief Executive Officer and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company.
He also held various executive positions with Life Technologies, Inc.(now Thermo Fisher Scientific) that included leading its global businesses, mergers and acquisitions and its initial public offering (“IPO”). Mr. Doerfler plays an active role as a life sciences industry advocate, serving as Chair Emeritus of the Maryland Tech Council and on the executive committee of the Biotechnology Innovation Organization.
Mr. Doerfler received his BS in finance from the University of Baltimore School of Business, and holds a certificate in Industrial Relations.
Chief Financial Officer
Mr. Holtz serves as MaxCyte’s Chief Financial Officer (CFO), having joined the Company in 2005. Previously, he has been CFO of both public and private companies and has raised more than $100 million in debt and equity capital. He also had previous experience with Ernst & Young LLP’s Financial Advisory Services Group. He earned an MBA in finance from the University of Maryland, a BS in mathematics from the University of Wisconsin and is a Certified Public Accountant.
Claudio Dansky Ullmann, MD
Chief Medical Officer
Dr. Dansky Ullmann, a 25+-year expert in clinical oncology and pharmaceutical research, is responsible for overseeing clinical development of MaxCyte’s CARMA™ drug development program. Dr. Dansky Ullmann was most recently the senior vice president and head of clinical development at Infinity Pharmaceuticals, where, as part of the executive leadership team, he oversaw all clinical development and operations, shaped corporate strategy, and was directly involved in business development activities as well as investor and analyst interactions. Previously, he was a senior medical director and global clinical lead for oncology clinical research in the Oncology Therapy Area Unit at Takeda Pharmaceuticals. Before joining Takeda, Dr. Dansky Ullmann worked at the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI) as a senior investigator participating in numerous early-phase and late-phase clinical trials. During his career, he also held research roles at the National Institute of Health and held postdoctoral fellowship positions in tumour immunotherapy and drug resistance at the NCI. He also was involved in the development of cell therapies and other immunotherapies at Biomira, Inc. Dr. Dansky Ullmann is a native of Argentina and earned his M.D. at the School of Medicine, University of Buenos Aires. He completed his medical oncology training at Guemes Private Hospital, Buenos Aires.
Executive Vice President, Global Commercial Operations
Mr. Calvin is a 25-year veteran within the diagnostics, devices, drug discovery and life sciences industries. In his role as MaxCyte’s EVP of Global Commercial Operations, he is responsible for leading the Company’s sales, marketing and business development functions to define product strategy, deliver new products and drive growth of its drug discovery and cell therapy businesses. Mr. Calvin was most recently Co-founder and President of AsedaSciences, a company with an integrated technology platform to predict in vivo toxicity risk in early-stage drug discovery. Previously, he has held various global and regional leadership positions at companies ranging from large corporations to start-ups, such as Accuvein, Beckman Coulter, Qiagen, Digene, AGENIX, and Abbott Laboratories. He has a Bachelor’s degree in Applied Science from Curtin Institute of Technology in Perth, Western Australia.
Thomas M. Ross
Executive Vice President, Global Sales
Mr. Ross serves as MaxCyte’s Executive Vice President of Global Sales, having joined the Company in 2014. Mr. Ross has extensive experience in all elements of commercial operations and has more than 25 years of successful sales and marketing leadership in the Life Science and Clinical Diagnostics markets. Most recently, Mr. Ross was Senior Vice President of Commercial Operations at OpGen®. Mr. Ross also served as Chief Commercial Officer at Predictive BioScience and Vice President of North America Medical Diagnostics Sales at Qiagen/Digene Corporation. Prior to working at Digene Corporation, he held several senior leadership roles in Manufacturing Operations at Life Technologies, Inc. and Cambrex. Mr. Ross has a Bachelor’s of Business Administration from The Citadel.
James Brady, PhD
Vice President, Technical Applications and Customer Support
Dr. Brady is Vice President of Technical Applications and Customer Support at MaxCyte, Inc. Prior to joining MaxCyte in 2004, Dr. Brady was a Senior Scientist at Genetic Therapy, Inc., a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments for ocular disorders. Previously, he worked at MetaMorphix, Inc. as a Group Leader in the Company’s Transgenic Livestock program, and was a postdoctoral fellow at the National Eye Institute of the National Institutes of Health. Dr. Brady received a Bachelor of Science degree in biology from the College of William and Mary, a Ph.D. in genetics from Indiana University and an MBA from Johns Hopkins University.
Vice President, Quality and Technical Operations
Mr. Kuo currently serves as MaxCyte’s Vice President of Quality and Technical Operations, having joined the Company in 2017. He has more than 20 years of biopharmaceutical and academic experience in developing cell, gene and regenerative medicine therapies. Mr. Kuo has established and directed numerous GMP manufacturing, quality assurance and analytical testing operations as well as provided oversight of global contract manufacturing and development organizations (CDMOs) and contract testing laboratories (CTLs). Prior to joining MaxCyte, Mr. Kuo served as Senior Director of Quality Assurance at Mesoblast, where he supported multiple global Phase III clinical studies. Previously, he held various leadership positions at BloodWorks Northwest, Cryo-Cell International, Aesculap Implant Systems and Amgen, providing oversight of process development, translational scale up, technology transfer and analytical testing. Mr. Kuo received his BS degrees in Medical Technology and Microbiology as well as his Biomedical Regulatory Affairs Certificate from the University of Washington.
Vice President, Legal
Mr. Masoud brings to MaxCyte 12 years of experience as an attorney and general counsel in the biotech industry. He has served as Assistant General Counsel and Corporate Secretary for Wellstat Management Company; co-founding partner of Rossi/Masoud LLC, a specialized law firm for the biotech, pharmaceutical and IT sectors; and Corporate Attorney at Human Genome Sciences, Inc. Mr. Masoud managed the legal team on the launch of two FDA-approved drugs while at Wellstat. At Human Genome Sciences, he assisted with FDA compliance for the product launch of Benlysta®, negotiated and executed more than 1,000 clinical trial agreements, negotiated licensing deals valued at over $300 million, and assisted the company with raising financing through bond and secondary stock offerings in excess of $800 million. A member of the Maryland State Bar, Mr. Masoud holds a JD from Michigan State University College of Law, and a BS in Cell & Molecular Biology Genetics from the University of Maryland.
Vice President, Regulatory
Dr. Wekselman is a senior drug development expert with extensive experience in drug development, clinical protocol development and execution, and interactions with regulatory authorities, including leading or developing marketing application submissions to the U.S. Food and Drug Administration (FDA), the European Medicines Agency and Health Canada for drugs, biologics and medical devices. She has 11 years of clinical research organization experience as a consultant to pharmaceutical, biotechnology, and device companies, and nine years at Procter & Gamble Pharmaceuticals, where she held positions in medical writing, medical monitoring, and project leadership. Dr. Wekselman earned her BSN (summa cum laude) and PhD in nursing from the University of Cincinnati. She had 10 years of clinical and academic experience in nursing before joining the industry to work in drug development. She has authored more than 25 journal articles or book chapters and has presented more than 30 posters, conference sessions, guest lectures and professional education seminars.
AIM Securities in Issue
|Intersouth Partners VI, L.P.||7,986,599||13.9%|
|River and Mercantile Asset Management Ltd||6,441,207||11.2%|
|Legal & General Investment Management Ltd||4,197,183||7.3%|
|Harbert Venture Partners, LLC||3,952,571||6.9%|
|Hargreave Hale Nominees Limited||3,896,553||6.8%|
|Unicorn AIM VCT||3,017,857||5.3%|
|Blackrock Inv Mgmt (UK) Limited||2,130,518||3.7%|
22 Firstfield Road, Suite 110
Gaithersburg, MD 20878
BioHub at Alderley Park
MaxCyte has appointed Panmure Gordon to act as nominated advisor and joint corporate broker to the Company for the purposes of the AIM Rules for Companies.
One New Change
London, EC4M 9AF
Joint Corporate Broker
Numis Securities Limited
The London Stock Exchange Building
10 Paternoster Square
London EC4M 7LT
800 Towers Crescent Drive, Suite 1000
Tysons, VA 22182-6213
Link Asset Services
The Registry, 34 Beckenham Road
Beckenham, Kent, BR3 4TU
Travers Smith LLP
10 Snow Hill
London EC1A 2AL